Advertisement

L'Endocrinologo

, Volume 19, Issue 4, pp 191–195 | Cite as

Approccio diagnostico e terapeutico agli adenomi ipofisari TSH-secernenti

  • Andrea Lania
  • Federico Gatto
Rassegna
  • 50 Downloads

Sommario

Gli adenomi ipofisari TSH-secernenti (TSHomi) rappresentano una rara causa di ipertiroidismo, in cui la secrezione di TSH è svincolata dal normale feedback degli ormoni tiroidei. I segni, sintomi e i dati biochimici nei pazienti con TSHoma sono in gran parte sovrapponibili a quelli osservati nella sindrome da resistenza agli ormoni tiroidei (RTH). La terapia di prima linea dei TSHomi è quella chirurgica, mentre gli analoghi della somatostatina sono efficaci nel normalizzare la secrezione ormonale nei pazienti non guariti dopo chirurgia o non candidabili all’approccio chirurgico.

Parole chiave

Adenoma ipofisario TSH Ormoni tiroidei Inappropriata secrezione di TSH Analoghi della somatostatina 

Notes

Conflitto di interesse

Gli autori Andrea Lania e Federico Gatto dichiarano di non avere conflitti di interesse.

Consenso informato

Lo studio presentato in questo articolo non ha richiesto sperimentazione umana.

Studi sugli animali

Gli autori di questo articolo non hanno eseguito studi sugli animali.

Supplementary material

40619_2018_456_MOESM1_ESM.doc (26 kb)
(DOC 27 kB)
40619_2018_456_MOESM2_ESM.doc (25 kb)
(DOC 25 kB)

Bibliografia

  1. 1.
    Ónnestam L, Berinder K, Burman P et al. (2013) National incidence and prevalence of TSH-secreting pituitary adenomas in Sweden. J Clin Endocrinol Metab 98:626–635 CrossRefGoogle Scholar
  2. 2.
    Beck-Peccoz P, Persani L, Mannavola D et al. (2009) Pituitary tumours: TSH-secreting adenomas. Best Pract Res Clin Endocrinol Metab 23:597–606 CrossRefGoogle Scholar
  3. 3.
    Beck-Peccoz P, Lania A, Persani L (2016) TSH-producing adenomas. In: Jameson LJ, DeGroot LJ (eds) Endocrinology, adult and pediatric, II, 7th edn. Saunders Elsevier, Philadelphia, pp 266–274 CrossRefGoogle Scholar
  4. 4.
    Teramoto A, Sanno N, Tahara S et al. (2004) Pathological study of thyrotropin-secreting pituitary adenoma: plurihormonality and medical treatment. Acta Neuropathol 2004:108–147 Google Scholar
  5. 5.
    Perticone F, Pigliaru F, Mariotti S et al. (2015) Is the incidence of differentiated thyroid cancer increased in patients with thyrotropin-secreting adenomas? Report of three cases from a large consecutive series. Thyroid 25(4):417–424 CrossRefGoogle Scholar
  6. 6.
    Koulouri O, Moran C, Halsall D et al. (2013) Pitfalls in the measurement and interpretation of thyroid function tests. Best Pract Res Clin Endocrinol Metab 27:745–762 CrossRefGoogle Scholar
  7. 7.
    Beck-Peccoz P, Lania A, Beckers A et al. (2013) European Thyroid Association guidelines for the diagnosis and treatment of thyrotropin-secreting pituitary tumors. Eur Thyroid J 2:76–82 CrossRefGoogle Scholar
  8. 8.
    Kobayashi S, Yoshimura Noh J, Shimizu T et al. (2017) A case of familial dysalbuminemic hyperthyroxinemia (FDH) in Japan: FDH as a possible differential diagnosis of syndrome of inappropriate secretion of thyroid-stimulating hormone (SITSH). Endocr J 64(2):207–212 CrossRefGoogle Scholar
  9. 9.
    Gurnell M, Visser TJ, Beck-Peccoz P et al. (2016) Resistance to thyroid hormone. In: Jameson LJ, DeGroot LJ (eds) Endocrinology, adult and pediatric, II, 6th edn. Saunders Elsevier, Philadelphia, pp 1648–1655 CrossRefGoogle Scholar
  10. 10.
    Malchiodi E, Profka E, Ferrante E et al. (2014) Thyrotropin-secreting pituitary adenomas: outcome of pituitary surgery and irradiation. J Clin Endocrinol Metab 99:2069–2076 CrossRefGoogle Scholar
  11. 11.
    Gatto F, Grasso LF, Nazzari E et al. (2015) Clinical outcome and evidence of high rate post-surgical anterior hypopituitarism in a cohort of TSH-secreting adenoma patients: might somatostatin analogs have a role as first-line therapy? Pituitary 18:583–591 CrossRefGoogle Scholar
  12. 12.
    Gatto F, Barbieri F, Gatti M et al. (2012) Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins. Clin Endocrinol (Oxf) 76:407–414 CrossRefGoogle Scholar
  13. 13.
    Theodoropoulou M, Stalla GK (2013) Somatostatin receptors: from signaling to clinical practice. Front Neuroendocrinol 34:228–252 CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.U.O. Endocrinologia e Andrologia MedicaIRCCS Istituto Clinico HumanitasRozzanoItalia
  2. 2.Dipartimento di Scienze BiomedicheHumanitas UniversityRozzanoItalia
  3. 3.Endocrinologia, Dipartimento di Medicina Interna e Specialità Mediche (DIMI)Università degli Studi di GenovaGenovaItalia

Personalised recommendations